Group items tagged

The SBIR program, as established by law, is intended to meet the following goals: stimulate technological innovation in the private sector; strengthen the role of small business in meeting Federal research or research and development (R/R&D) needs; increase the commercial application of Federally-supported research results; foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns in the SBIR program; and improve the return on investment from Federally-funded research for economic and social benefits to the Nation.

This Funding Opportunity Announcement (FOA) encourages the translation of technologies for brain or behavioral research from academic and other non-small business research sectors to the marketplace. Encouraged from Small Business Concerns (SBCs) are Small Business Innovation Research (SBIR) grant applications that propose to further develop, make more robust, and make more user-friendly such technologies in preparation for commercial dissemination. It is expected that this activity will require partnerships and close collaboration between the original developers of these technologies and SBCs, which may be accomplished in any of a number of ways, including the use of multiple program directors/principal investigators.

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery. The program will utilize the cooperative agreement mechanism to enable milestone-drive projects.

This Funding Opportunity Announcement (FOA) encourages the translation of technologies for brain or behavioral research from academic and other non-small business research sectors to the marketplace. Encouraged from Small Business Concerns (SBCs) are Small Business Innovation Research (SBIR) grant applications that propose to further develop, make more robust, and make more user-friendly such technologies in preparation for commercial dissemination. It is expected that this activity will require partnerships and close collaboration between the original developers of these technologies and SBCs, which may be accomplished in any of a number of ways, including the use of multiple program directors/principal investigators.

This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH.

This Funding Opportunity Announcement (FOA) utilizes the Small Business Innovation Research Program (SBIR) award mechanism to support the development of highly engaging cognitive training interventions delivered through computers and/or gaming platforms that are targeted to the treatment of neuropsychiatric disorders, autism and/or HIV Associated Neurocognitive Disorders (HAND), with the goal of improving real-world functioning of patients. This initiative specifically supports small businesses with development and commercial experience in the entertainment software industry to partner with clinical neuroscientists experienced with cognitive training.

There is a need to develop technologies that support research using zebrafish models of biomedical value. The zebrafish has become increasingly important as a biological resource, because of its small size, short generation time, easy manipulation of embryos and optical transparency. This animal model is used to study aspects of gene structure and function that can be directly related to human genetics and disease. Zebrafish are also important for studies in diverse disciplines, including pharmacology, toxicology, neurobiology, behavior and developmental biology. This funding opportunity announcement (FOA) encourages applications from small business concerns (SBCs) for Small Business Innovation Research (SBIR) projects that propose innovative research and development of technology, including reagents and high throughput equipment, to support different aspects of the creation, detection, identification and characterization of zebrafish models of human disease and preservation of genetic stocks.

Join BioOhio and the Columbus chapter of the Healthcare Businesswomen's Association (HBA) for a FREE online event - our second Diversity in Bioscience & Healthcare event of 2020, on August 20 at 5 pm. The engaging discussion focuses on the importance of supporting STEM programming at an early age within under-represented communities to encourage careers within the science and healthcare industries. Our special guests include: Frederic Bertley, Ph.D., President & CEO, COSI Kirsten M. Ellenbogen, Ph.D., President & CEO, Great Lakes Science Center Kelly Lewis, Bioscience Technologies Program Instructor, Eastland-Fairfield Career and Technical Schools Lead by the talented Brooke Cartus, Director of Business Development and Senior Facilitator, ImprovEdge! Featuring networking opportunities during the event! This discussion will be held via Zoom. Login instructions are included in your registration confirmation email and reminder emails sent before the event. BioOhio and the Healthcare Business Women's Association (HBA) support all efforts to increase diversity and inclusion within the bioscience and healthcare industries and invite you to join us for our next discussion, Overcoming Obstacles in the Workplace: Making Work Accessible on November 14th, 2020. This event is brought to you by BioOhio in partnership with the Columbus chapter of the Healthcare Businesswomen's Association (HBA) and is made possible by the generous support of BioOhio members AtriCure and BIO.

In this Funding Opportunity Announcement (FOA) we seek applications through the Small Business Innovation Research (SBIR) program for the optimization of existing and emerging technologies and approaches including 1) technologies and novel approaches for large scale recording and manipulation of neural activity, at or near cellular resolution, at multiple spatial and/or temporal scales, in any region and throughout the entire depth of the brain, 2) tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. This FOA is intended for the iterative refinement of emergent technologies and approaches that have already demonstrated their transformative potential through initial proof-of-concept testing, and are appropriate for accelerated development with an end-goal of broad dissemination and incorporation into regular neuroscience practice.

The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research, including 1) tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function, 2) proof-of-concept testing and development of new technologies and novel approaches for large scale recording and manipulation of neural activity, at or near cellular resolution, at multiple spatial and/or temporal scales, in any region and throughout the entire depth of the brain, and 3) iterative refinement of such tools and technologies with the end-user community with an end-goal of scaling manufacture towards reliable, broad, sustainable dissemination and incorporation into regular neuroscience practice.     

The New Era of University Innovation & Commercialization This panel discussion examines the future of university and business collaboration, with a focus on inclusive innovation. Thursday, April 19, 2018 from 3:30 PM to 4:45 PM (EDT) Oxford, OH

The Alzheimer's Drug Discovery Foundation has issued a Request for Proposals for its Preclinical Drug Discovery program. Through the program, grants of up to $600,000 over two years will be awarded to promising preclinical drug discovery programs relevant to Alzheimer's disease, related dementias, and cognitive aging. Preclinical research funding priorities include high throughput screening, medicinal chemistry hit-to-lead development and optimization, in vitro and in vivo efficacy studies, ADME, toxicology, pharma-cokinetics and pharma-co-dynamics, and in vivo proof-of-concept with lead compounds and biologics. Program areas of particular interest include new chemical compounds for Alzheimer's disease, preclinical proof-of-concept, and re-purposing. With regards to potential drug targets, ADDF is interested in novel targets that include but are not limited to neuro-inflammation, protein degradation/autophagy, growth factor signaling, synaptic function/morphology, calcium regulation, energy utilization/mitochondria function, insulin sensitivity, epigenetics, ApoE function and cholesterol metabolism, vascular injury and the blood-brain barrier interface, cognitive enhancers, myelin changes, ischemia and oxidative stress, and tau-related toxicities. To be eligible, applicants must be academic investigators seeking to create and support innovative translational programs in academic medical centers and universities; biotechnology companies with programs dedicated to Alzheimer's disease translational development; and new biotechnology company spinouts or existing biotechnology companies that demonstrate a clear need for nonprofit funding. Funding is provided through program-related investments (PRIs) that require a return on investment based on scientific and/or business milestones.

The English Speaking Union of the United States each year sponsors a travel grant for study or research providing a stipend of up to $2,000. This competition is open to qualified under-graduate and post-graduate students, faculty, and others involved in academic pursuits that are in accord with the goal of the English Speaking Union of promoting education and understanding among the English speaking peoples of the world. The grant is designed to assist worthy individuals who are active in the fields of Business, the Humanities, Science and Engineering, Liberal, Fine or Applied Arts and who wish to study or conduct research either in the United States or in one of the countries of the British Commonwealth.

Reissue of PAR-18-541. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

The Defense Advanced Research Projects Agency (DARPA) Defense Sciences Office (DSO) is sponsoring an event (D3) to (1) familiarize attendees with DSO's mission and the nature of the efforts we support; (2) promote understanding of how to do business with DSO and (3) facilitate discussions with potential performers. The event is scheduled for Thursday, June 15, 2017 at the DoubleTree Crystal City (300 Army Navy Drive Arlington, VA 22202); selected sessions will be webcast for those who would like to participate remotely.  Advance registration is required for attending the event in person or for viewing the webcast.

Grants of up to $150,000 will be awarded for research on the pathologic mechanisms underlying FTD. Priority will be given to projects related to the development and testing of novel high-throughput screening assays; identification and in vitro testing of potentially disease modifying compounds or biologics, including medicinal chemistry refinement, ADME, toxicology, pharmacokinetics, and pharmacodynamics studies; testing of novel lead compounds, biologics, or repurposed drug candidates in a relevant animal model for preclinical proof of concept; and/or development and/or characterization of new model organisms or cellular models in support of drug-discovery efforts. Funding is provided through mission-related investments that require return on investment based on scientific and/or business milestones.

The 2017 Building Trust and Mutual Respect to Improve Health Care call for proposals (CFP) will fund empirical research studies to help us better understand how to build trust and mutual respect to meet vulnerable patients' health care needs. For this CFP, we would define vulnerable populations in a number of different ways, including the economically disadvantaged, diverse racial and ethnic populations, the uninsured, older adults, homeless individuals, and people with complex health and social needs (including people with acute behavioral health needs or multiple chronic conditions). Proposals most closely aligned with the scope of this CFP will go beyond documenting the problem to generate findings that will be generalizable and have broad application across health systems and the field. Eligibility and Selection Criteria · Researchers, as well as practitioners in the public and private sector working with researchers, are eligible to submit proposals through their organizations. Projects may be generated from disciplines including health services research; economics; sociology; program evaluation; political science; public policy; psychology; public health; public administration; law; business administration; or other related fields. · The Foundation may give preference to applicants that are either public entities or nonprofit organizations that are tax-exempt under Section 501(c)(3) of the Internal Revenue Code and are not private foundations or Type III supporting organizations. · The Foundation may require additional documentation. Applicant organizations must be based in the United States or its territories.

Applicants for the funds may be students or faculty. The project, program, or entrepreneurial idea must be created by, led by or benefit women. Grants are awarded in values of $2500 to $20,000. While we prefer the base grant to be $5,000, we are considering a limited number of $2500 which will be required to show high impact. These applicants will be considered on a case-by-case basis. The grants must be submitted online via the link below and must include a 2-minute video. Applicants will be narrowed to a pool of 10-15 finalists by our M.I.A.M.I. WOMEN Grants Committee. This committee will review applications; contact applicants if additional information is required, and present the finalists to the M.I.A.M.I. WOMEN Steering Committee and Development Staff. Grant deadline for this year is Feb. 9, 2018. These finalists will perform in a fast-pitch style Hawk Tank event on April 11, 2018. Finalists will be offered fast-pitch training courtesy of the Farmers School of Business - school of Entrepreneurship, and will receive coaching and support. They will then pitch their idea in 5 minutes or less on April 11, 2018 at the event. Giving Circle members are the voters who will determine winners. Absentee voters will be given the option to vote online. Winners will be announced that night or the next day at the Symposium, to be determined.

This funding opportunity (FOA) encourages small business technology transfer STTR research and development of commercial pharmaceutical interventions to extend lifespan and/or healthspan, to prevent, treat, and/or slow the progression of symptoms associated with Alzheimer's disease (AD) or Alzheimer's disease related dementia (ADRD) in human cells and/or tissue, in-vitro models, and/or non-human animals.

The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.